SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

21 marketing jobs

Johnson & Johnson logo
7 months ago

Director, Global Strategic Marketing, Cardiac Imaging & Structural Heart (Irvine, CA) Johnson and Johnson, MedTech Electrophysiology

Johnson & Johnson

Irvine, CA (On-site)Full time$150K/yr – $259K/yr
Previous
12
Next

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

21 jobs
Johnson & Johnson logo

Director, Global Strategic Marketing, Cardiac Imaging & Structural Heart (Irvine, CA) Johnson and Johnson, MedTech Electrophysiology

Johnson & Johnson

Irvine, CA (On-site)

$150K/yr - $259K/yrIn-houseFull-timeDirector/executive10+ years exp.
7 months ago
Previous12
Johnson & Johnson logo
Johnson & Johnson

Director, Global Strategic Marketing, Cardiac Imaging & Structural Heart (Irvine, CA) Johnson and Johnson, MedTech Electrophysiology

Irvine, CA (On-site)

$150K/yr – $259K/yrDirector/Executive10+ years expFull time

Posted 7 months ago

  • Job
  • Company
  • Salaries
  • People
  • Audience
  • News
  • Links

Job Summary

Drive global portfolio strategy and launches for Structural Heart imaging; lead cross-functional execution to turn clinical needs into next-gen solutions.

  • Own the 5-year roadmap, R&D alignment and M&A input for Structural Heart imaging.
  • Must-have: 10+ years in imaging or device marketing/sales with cardiovascular domain.
  • Standout: Proven cross-functional leadership across Commercial, R&D, and Education to execute launches.

Job Description

Responsibilities

  • Own the multi‑year global portfolio and business plan (including 5‑year roadmap, R&D alignment, and M&A input) for Structural Heart imaging products to drive growth in interventional cardiology.
  • Define procedural roadmaps and playbooks (e.g., TEE→ICE conversion), remove adoption barriers, and shape the imaging role within the multidisciplinary Heart Team and cath‑lab workflow.
  • Lead product and technology strategy across hardware, catheters, software and AI; prioritize pipeline investments, translate clinical needs into requirements, and partner with R&D to deliver next‑generation solutions.
  • Create clear value propositions, segmentation, pricing and global/regional launch plans; drive market‑focused demand generation and adoption strategies across regions.
  • Own evidence generation and clinical claims strategy, ensure clinical input is integrated into product design, and translate outcomes into economic and clinical value messaging for payers and providers.
  • Lead cross‑organizational execution with Commercial, R&D, Global Education, Program Management, Regional Marketing and Business Development to operationalize strategy and product launches.
  • Direct market and competitive intelligence to inform positioning, lifecycle decisions and response plans; continually scan for disruptive trends and competitor actions.
  • Cultivate relationships with interventional cardiologists, surgeons, and imaging specialists to shape the "Heart Team" dynamic.

Requirements

  • Bachelor’s degree in Business Administration, Marketing, Engineering or related field required.
  • Advanced degree (e.g., M.B.A.) is highly preferred.
  • 10+ years of relevant business experience in Marketing or Sales, or a related field is required, ideally with a leading imaging or device company.
  • Cardiovascular industry and clinical structural heart knowledge with proven ability to learn complex technology/clinical applications required.
  • Clinical Depth: Deep understanding of the technical requirements of imaging-guided interventions and the spatial nuances of 4D ICE vs. TEE.
  • Digital Fluency: Experience working with software engineers on AI/Machine Learning integration to improve image processing and clinical utility.
  • Financial & Economic Acumen: Ability to develop financial and market forecasts and articulate the ROI of procedural efficiency.
  • Effective management in a matrix organization and the talent to act as an organizational change agent and leader are required.
  • Proven behaviors as a strong partner and team player, especially with functions including global education, R&D, commercial field leadership, regulatory affairs, clinical affairs and operations/planning/manufacturing.
  • Ability to travel globally up to 30% for customer engagement and major clinical congresses.

Preferred

  • Advanced degree (e.g., M.B.A.) is highly preferred.

Benefits

  • Employees are eligible for medical, dental, vision, life insurance, short- and long-term disability, business accident insurance, and group legal insurance.
  • Employees may be eligible to participate in the Company’s consolidated retirement plan (pension) and savings plan (401(k)).
  • This position is eligible to participate in the Company’s long-term incentive program.
  • Vacation – up to 120 hours per calendar year
  • Sick time - up to 40 hours per calendar year; for employees who reside in the State of Washington – up to 56 hours per calendar year
  • Holiday pay, including Floating Holidays – up to 13 days per calendar year
  • Work, Personal and Family Time - up to 40 hours per calendar year
  • Parental Leave – 480 hours within one year of the birth/adoption/foster care of a child
  • Bereavement Leave – 240 hours for an immediate family member: 40 hours for an extended family member per calendar year
  • Caregiver Leave – 80 hours in a 52‑week rolling period10 days
  • Volunteer Leave – 32 hours per calendar year
  • Military Spouse Time-Off – 80 hours per calendar year
  • For additional general information on Company benefits, please go to: https://www.careers.jnj.com/employee-benefits
Johnson & Johnson logo

Johnson & Johnson

4.1 Glassdoor

At Johnson & Johnson, we believe health is everything. As a focused healthcare company, with expertise in Innovative Medicine and MedTech, we’re empowered to tackle the world’s toughest health challenges, innovate through science and technology, and transform patient care. All of this is possible because of our people. We’re passionate innovators who put people first, and through our purpose-driven culture and talented workforce, we are stronger than ever. Learn more at https://www.jnj.com. Community Guidelines: http://www.jnj.com/social-media-community-guidelines

Founded in 1953
New Brunswick, New Jersey, USA
116K employees (4,854 in marketing)
www.jnj.com
83% recommend to a friend
86% CEO approval

Salaries

Posted range

$150K/yr – $259K/yr

Taken straight from the job posting.

See all Johnson & Johnson salaries

Marketing Team

Marketing Team Size
4,042 (3% of company)
Median Career Experience
18 years
Median Tenure
10.8 years
Marketing Roles Posted (Last 30 Days)
6

People

HR / Recruitment

Clara Goyanes
Clara Goyanes
Global Head of Talent Acquisition, Employer Brand and Digital Marketing
At the company for 3 years 8 months

Marketing Leadership

Andrew Holland
Andrew Holland
Vice President - Key Account Management, Customer Marketing, Pricing & Offer Development
At the company for 21 years 3 months
John Haney
John Haney
Vice President | Healthcare Strategic Marketing | Enterprise Customer Group
At the company for 37 years 7 months
Crystal Simon, PhD
Crystal Simon, PhD
Head of Downstream Marketing - MONARCH
At the company for 1 year 4 months
Marc Palomeque Castilla
Marc Palomeque Castilla
Global Strategic Marketing Head Vision Care
At the company for 1 year 11 months

Traffic Signals

Monthly Visitors
2.2M
Monthly Google Ads Budget
$331K
Traffic Source Mix
Search
36.1%
Direct
46.5%
Referral
15%
Social
1.3%
Paid
0.9%

Headcount Trend

Current headcount: ~115.7K

Recent News

Johnson & Johnson reports high clearance rates for psoriasis drug
Oct 24, 2025 • Investing.com
Carnegie Investment Counsel Sells 3,037 Shares of Johnson & Johnson $JNJ
Oct 24, 2025 • MarketBeat
Cadinha & Co. LLC Has $1.64 Million Stock Holdings in Johnson & Johnson $JNJ
Oct 24, 2025 • MarketBeat
Johnson & Johnson $JNJ Stake Lifted by Smith Group Asset Management LLC
Oct 24, 2025 • MarketBeat
Johnson & Johnson $JNJ Stock Holdings Lessened by First Citizens Bank & Trust Co.
Oct 24, 2025 • MarketBeat
Ethic Inc. Increases Stake in Johnson & Johnson $JNJ
Oct 24, 2025 • MarketBeat
Johnson & Johnson to collaborate with the New York Jets to promote better health in the community
Oct 22, 2025 • Johnson & Johnson
J&J faces first UK lawsuits alleging its baby powder caused cancer
Oct 16, 2025 • Reuters
6 FDA Decisions to Watch For in Q4
Sep 29, 2025 • BioSpace
Hundreds Attend IRA Implementation Summit; Uncertainties, Confusion and Concerns About Service Levels Underscore Dialogue
Sep 29, 2025 • BioSpace
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
Sep 29, 2025 • MarketScreener
U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
Sep 29, 2025 • PR Newswire
September’s FDA Action Bolsters Keytruda, Ultra-Rare Disease but Deals Two SMA Defeats
Sep 29, 2025 • BioSpace
Surgical Staplers Market To Grow US$ 10,587.21 Million By 2033, Registering A Robust CAGR Of 5.9% | Business Market Insights
Sep 29, 2025 • PR Newswire
Johnson & Johnson Gets FDA Approval for Pediatric Psoriasis, Arthritis
Sep 29, 2025 • MarketScreener
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of investigational targeted oral peptide for treatment of plaque psoriasis
Sep 29, 2025 • PharmiWeb
Smart Suturing Systems Market to Reach USD 6,824.9 Million by 2035, Driven by Minimally Invasive Surgery Demand
Sep 29, 2025 • EIN Presswire
Why Microsoft Has Lower Borrowing Costs Than the U.S.
Sep 28, 2025 • WSJ.com: Markets
Why Johnson & Johnson Could Be the Ultimate Dividend King
Sep 28, 2025 • Yahoo Finance
Lawyers facing big paydays from Tylenol attack | READER COMMENTARY
Sep 28, 2025 • Baltimore Sun
Why Johnson & Johnson Could Be the Ultimate Dividend King
Sep 28, 2025 • The Motley Fool
Johnson & Johnson (JNJ) to Withdraw the LINC Reflux Management System from Markets Outside the U.S.
Sep 27, 2025 • Yahoo Finance
Pharma firms still keen to grow in S’pore but investment climate will get more competitive: DPM Gan
Sep 27, 2025 • Straits Times
Trump threatens 100% tariffs on drugmakers who aren't building U.S. plants
Sep 26, 2025 • Axios
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Sep 26, 2025 • BioSpace
J&J: Still a Defensive Giant, or Too Dependent on Pharma?
Sep 26, 2025 • GuruFocus
Rheumatoid Arthritis Therapeutics Market Trends Analysis Report 2025-2033 by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter)
Sep 26, 2025 • Research and Markets
Jabils AI-Driven Boom Has Begun: News Highs are Coming
Sep 26, 2025 • MarketBeat
Big pharma stocks rise as Street reacts to latest presidential tariff plan
Sep 26, 2025 • San Francisco Chronicle
Trump to put tariffs on heavy trucks, citing need to protect Mack Trucks, other US manufacturers from ‘unfair outside competition’
Sep 26, 2025 • The Morning Call
Global drugmakers rush to boost US presence as tariff threat looms
Sep 26, 2025 • Reuters
Trump announces new tariffs on pharmaceuticals from October
Sep 26, 2025 • Irish Times
Big pharma stocks rise as Street reacts to latest presidential tariff plan
Sep 26, 2025 • Press Telegram
Intel, Johnson & Johnson and Boeing rise premarket; Wayfair falls
Sep 26, 2025 • Investing.com
3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years
Sep 25, 2025 • The Motley Fool
Revision Skincare Appoints Lisa Paley as CEO
Sep 25, 2025 • citybiz
Craniomaxillofacial Devices Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034
Sep 25, 2025 • Research and Markets
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
Sep 25, 2025 • BioSpace
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Sep 25, 2025 • Nuvectis Pharma, Inc.
US stock futures flat amid Trump tariff barrage; PCE inflation on tap
Sep 25, 2025 • Investing.com
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
Sep 25, 2025 • AC Immune SA
ANRF Opens 2026–2027 Research Grants, Driving New Solutions for Arthritis and Autoimmune Diseases
Sep 25, 2025 • EIN Presswire
Trump’s claims linking Tylenol use during pregnancy to autism: An AIIMS expert unpacks
Sep 24, 2025 • Indian Express
Tylenol Maker Kenvue Faces Mounting Crisis After Trump Blast
Sep 24, 2025 • Livemint.com
Fujifilm Biotechnologies cuts ribbon on $3.2B antibody facility in N.C.
Sep 24, 2025 • FiercePharma
SGLT2 blocker market poised for growth as competition heats up
Sep 24, 2025 • Pharma Letter
BMS eyes filings for myeloma 'celmod' iberdomide
Sep 24, 2025 • pharmaphorum
FDA Hits J&J With Warning Letter Over ‘Significant Violations’ at Korean Production Plant
Sep 24, 2025 • BioSpace
Transcript : Johnson & Johnson Presents at Bernstein 2nd Annual Global Healthcare Conference, Sep-24-2025 01
Sep 24, 2025 • MarketScreener
Economist Impact's 5th edition Future of Health Asia returns to Singapore amid rising technological disruption, chronic disease burdens and international trade tensions
Sep 23, 2025 • PR Newswire UK
AAMI Foundation Awards Grants to Hospital, University Research Teams
Sep 23, 2025 • AAMI
Johnson & Johnson to withdraw acid reflux device from markets outside U.S.
Sep 23, 2025 • Investing.com
Fate Therapeutics Gets J&J Partnership Class Action Tossed Again
Sep 23, 2025 • bloomberglaw.com
J&J to withdraw acid reflux device from certain markets
Sep 23, 2025 • MarketScreener
Tylenol maker rebounds a day after Trump’s unfounded claims about its safety
Sep 23, 2025 • Sun Sentinel
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Sep 23, 2025 • Benzinga.com
Trump’s unfounded claims heap new stress on household brand name Tylenol
Sep 23, 2025 • San Bernardino Sun
Tylenol-maker Kenvue shares bounce back, Trump claims face pushback
Sep 23, 2025 • Investing.com
STAT+: Pharmalittle: We’re reading about a GSK drug reapproved for autism, Kenvue’s Tylenol nightmare, and more
Sep 23, 2025 • STAT
Tylenol parent’s stock rises despite Trump autism claims
Sep 23, 2025 • semafor.com
Tylenol maker rebounds a day after Trump’s unfounded claims about its safety
Sep 23, 2025 • BNN Bloomberg
Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors
Sep 23, 2025 • Benzinga.com
Trump’s unfounded claims heap new stress on household brand name Tylenol
Sep 23, 2025 • Twin Cities
The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now
Sep 23, 2025 • The Motley Fool
Guselkumab receives CHMP backing for subcutaneous induction in ulcerative colitis
Sep 22, 2025 • Pharma Times
Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)
Sep 22, 2025 • BioSpace
TREMFYA (guselkumab) receives positive CHMP opinion for subcutaneous induction regimen in ulcerative colitis, a first for an IL-23 inhibitor
Sep 22, 2025 • BioSpace
Kenvue says Tylenol is safe, but stock hits record low as Trump makes unproven link to autism
Sep 22, 2025 • Morningstar.com
Trump links autism with Tylenol, a claim many doctors dispute
Sep 22, 2025 • MarketScreener
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 22, 2025 • BioSpace
Global Cell Biology Research Market 2024-2030: Advances in Single-Cell Technologies and Genomics Tools Driving Transformational Growth
Sep 22, 2025 • Research and Markets
Positive results for J&J's seltorexant in major depression
Sep 22, 2025 • MarketScreener
Psychedelics Space Enters New Era as AbbVie Dives In
Sep 22, 2025 • BioSpace
Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis
Sep 22, 2025 • NYT > Business
Celltrion wins Japan nod for Avtozma, 1st Actemra copy
Sep 22, 2025 • KED Global
Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030: Advances in Next-Gen Immunotherapies, AI, and Biomarker-Driven Personalization are Driving Transformational Growth
Sep 22, 2025 • Research and Markets
Alvotech, Partner Say European Medicines Agency Recommends Gobivaz Marketing Approval
Sep 22, 2025 • MarketScreener
Trump expected to link autism with Tylenol, a claim highly disputed
Sep 22, 2025 • MarketScreener
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
Sep 21, 2025 • The Motley Fool
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 19, 2025 • Morningstar.com
Johnson & Johnson announces positive CHMP opinion of nipocalimab
Sep 19, 2025 • thefly.com
Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)
Sep 19, 2025 • Janssen EMEA
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 19, 2025 • MarketScreener
J&J receives positive CHMP opinion of nipocalimab to treat generalised Myasthenia gravis (gMG)
Sep 19, 2025 • MarketScreener
JNJ: TECVAYLI/DARZALEX FASPRO regimen shows positive results in study
Sep 19, 2025 • thefly.com
Johnson & Johnson Says Induction Treatment Showed 'Meaningful' Efficacy in Multiple Myeloma Patients
Sep 19, 2025 • MarketScreener
Johnson & Johnson Announces an Investigational Immune-Based Indication Regimen with TECVAYLI®? (Te) and DARZALEX FASPRO®? (Daratumumab andhyaluronidase-fihj) Demonstrated Clinical Trial
Sep 19, 2025 • MarketScreener
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
Sep 19, 2025 • MarketScreener
Nakada retires from investor role at pharma group Johnson & Johnson
Sep 18, 2025 • globalventuring.com
Global Gastrointestinal Devices Market to Achieve 7% CAGR Rise with Growing Aging Population 2030
Sep 18, 2025 • PharmiWeb
Lysosomal Storage Disorders (LSDs) Market Set to Soar: Key Players Drive Innovative Treatments in 2025-2033
Sep 18, 2025 • EIN Presswire
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
Sep 18, 2025 • BioSpace
Big Pharma’s pullback from the UK could have serious side-effects for Ireland
Sep 18, 2025 • Irish Times
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
Sep 18, 2025 • Benzinga.com
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
Sep 18, 2025 • BioSpace
J&J Whistleblowers Defend $1.6B False Claims Act Win
Sep 18, 2025 • Law360
Cork Company of the Year Awards open for entries
Sep 17, 2025 • Irish Examiner
Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
Sep 17, 2025 • MarketScreener
Protagonist Announces Presentations of Clinical Data with...
Sep 17, 2025 • PharmiWeb
Johnson & Johnson's Icotrokinra Meets Co-Primary Endpoints in Phase 3 Plaque Psoriasis Trials
Sep 17, 2025 • MarketScreener

Links

www.jnj.comLinkedInX (Twitter)Crunchbase